

Johns Hopkins HealthCare Medical Policies Update

These medical policies have been approved by the JHHC MPAC (Medical Policy Advisory Committee), formerly known as the SEEPAC (Scientific Evidence Evaluation and Policy Advisory Committee), and the JHHC QAPI (Quality Assurance Process Improvement) committee, formerly known as the MPC (Medical Policy Committee).

Changes and additions are effective **4/16/18**.

Full text copies of these policies are available upon request by contacting Provider Relations at 888-895-4998.

To view all JHHC medical policies, please go to [Medical Policies page](#) on the JHHC website.

Medical Policy	Key Points/Changes	Status	Line of Business
CMS16.20 Proton Beam Radiotherapy	<p>New Policy</p> <ul style="list-style-type: none"> Proton therapy is a type of radiation treatment that uses protons to treat cancer. It delivers more radiation to the tumor while reducing side effects on normal tissues. 	Effective 4/16/18	Refer to policy for specific details.
CMS24.02 Long-Term External Cardiac Event Monitoring (Zio®Patch)	<p>New Policy</p> <ul style="list-style-type: none"> An adhesive patch used to detect arrhythmias in cases when a standard 24-48 hour Holter monitor would likely not provide a diagnosis. The Zio® Patch provides up to 14 days of continuous electrocardiographic (ECG) monitoring in order to detect arrhythmias in the setting of certain symptoms. 	Effective 4/16/18	Refer to policy for specific details.
CMS02.14 Reduction Mammoplasty	<p>Revised Policy</p> <ul style="list-style-type: none"> Added the following criteria to section I, letter B: headaches, medically supervised weight loss program, and orthopedic or spine surgeon evaluation of spinal pain Added the following criteria to 	Effective 4/16/18	Refer to policy for specific details.

	<p>section I, letter C: based on the member's body surface area (BSA) calculated using the Mosteller formula</p> <ul style="list-style-type: none"> Added the following criteria to section I, letter E: requests for reduction mammoplasty can be considered in females under 18 who have achieved sexual maturity [Tanner Stage V (e.g. breast size has been stable over 1 year)] for > 1 year on a case by case basis and criteria in specific sections of the policy are met Added the following criteria to section II, letter E: (delta-9-tetrahydrocannabinol which is the active ingredient in marijuana) Background and references reviewed and updated 		
CMS20.03 Gastroesophageal Reflux Disease (GERD) Devices	<p>Revised Policy</p> <ul style="list-style-type: none"> Added criteria which addresses magnetic sphincter augmentation (MSA) device (LINX® Reflux Management System) 	Effective 4/16/18	Refer to policy for specific details.
CMS09.04 Intradiscal Electrothermal Therapy (IDET)	<p>Revised Policy</p> <ul style="list-style-type: none"> Background and references reviewed and updated 	Effective 4/16/18	Refer to policy for specific details.
CMS16.15 Evaluation and Treatment of Pediatric Feeding Disorders	<p>Revised Policy</p> <ul style="list-style-type: none"> Background and references reviewed and updated 	Effective 4/16/18	Refer to policy for specific details.

[Go to the JHHC Medical Policies page](#)